Unusual genetic mutation found linked to adolescent liver cancer — ScienceDaily
source : http://www.sciencedaily.com/releases/2014/02/140228103510.htm
source : http://www.sciencedaily.com/releases/2014/02/140228103510.htm
The findings are based on research led by Raghu Kalluri, M.D., Ph.D., chairman and professor in MD Anderson’s Department of Cancer Biology. The research results appear in the current online edition of the Journal of Biological Chemistry. "At the present time, there is no single blood test that can screen for all cancer related DNA defects," said Kalluri. "In many cases, current protocols require a tumor sample to determine whether gene mutations and deletions exist and therefore determine whether the tumor itself is cancerous or benign. …
"We undertook this study because we wanted to learn what was driving the growth of these tumors and how best to treat them," says the study’s co-principal investigator, Dr. …
The findings of Rb’s role at multiple points in the disease process point to a potential new therapeutic target in patients with the most aggressive subset of breast cancer, known as basal-like breast carcinomas. This type of cancer has no estrogen receptor expression, and to date there is no efficient therapy for patients who suffer from it, leaving them with a generally poor prognosis. …
In research published recently in the journal Oncogene, Murray Korc, M.D., the Myles Brand Professor of Cancer Research at the Indiana University School of Medicine and a researcher at the Indiana University Melvin and Bren Simon Cancer Center, showed that an RNA molecule — microRNA-10b, or miR-10b — is present at high levels in the blood of most pancreatic cancer patients. Consequently, miR-10b could serve as a diagnostic marker as well as help physicians determine the disease’s aggressiveness…
Antiangiogenic drugs are anticancer drugs designed to cut off the blood supply that brings tumors the nutrients they need to grow and survive, thereby starving and killing the tumor cells. …
Dr Philip Poortmans, a radiation oncologist from the Institute Verbeeten, Tilburg, The Netherlands, and a member of the EORTC Radiation Oncology and Breast Cancer Groups, said that results from the international randomised trial, which involved 4004 patients from 43 centres, were convincing. "Our results make it clear that irradiating these lymph nodes give a better patient outcome than giving radiation therapy to the breast/thoracic wall alone…
Dr Christophe Le Tourneau, Head of the Phase I Programme at the Institut Curie, Paris, France, will tell the congress that the SHIVA trial is the first randomised trial to look at patient outcomes after treatments were chosen according to the individual molecular profiles of each person’s tumour. It is also the first trial to do this for all tumour types. About 40% of all those taking part in the trial have molecular abnormalities that can be targeted by existing drugs, he will say…
Stuck in what amounts to cellular adolescence, these precursor cells accumulate, contributing to the variability among glioblastoma multiforme (GBM) cells that make it so difficult to treat, said first author Jian Hu, Ph.D., instructor of Genomic Medicine. "This arrested development is driven by the GBM cells’ plasticity — their stem-cell-like ability to produce many types of cells — and the breakdown of the cellular maturation process known as terminal differentiation," said senior author and MD Anderson President Ronald DePinho, M.D…
source : http://www.foxnews.com/health/2013/06/26/mexico-restricts-us-live-hog-imports-due-to-piglet-virus/